[Federal Register Volume 68, Number 24 (Wednesday, February 5, 2003)]
[Notices]
[Pages 5905-5906]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-2620]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of 
the Recombinant DNA Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should inform the contact person listed below in 
advance of the meeting.

    Name of Committee: Recombinant DNA Advisory Committee (RAC).
    Date: February 10, 2003.
    Time: 8:30 am to 4:30 pm.
    Agenda: The Committee will review new data from a retroviral-
mediated gene transfer clinical trial in Severe Combined 
Immunodeficiency (SCID) that could be important to the safety of 
participants in gene transfer clinical trials that use retroviral 
vectors. The discussion of this new information may lead to changes 
in the recommendations on the safety of the clinical gene transfer 
trials in SCID formulated by the RAC at its December 2002 meeting. 
In addition, the RAC may make recommendations pertaining to the 
safety and conduct of gene transfer clinical trials using retroviral 
vectors.
    The RAC is meeting due to the potential significance of this new 
data and the need for expeditious deliberation and public discussion 
of its potential implications for the safety and conduct of clinical 
gene transfer trials using retroviral vectors.
    Place: National Institutes of Health, 9000 Rockville Pike, 
Building 45, Main Auditorium, Bethesda, Maryland 20892.
    Contact: Stephen Rose, Ph.D., Executive Secretary, Recombinant 
DNA Advisory Committee, Office of Biotechnology Activities, 
Rockledge 1, Room 750, Bethesda MD 20892, (301) 496-9839.

    This notice is being published less than 15 days before the meeting 
due to the emergency nature of the actions involved.
    Information is also available on the Institute's/Center's home 
page: http://www4.od.nih.gov/oba/, where an agenda and any additional 
information for the meeting will be posted when available.
    OMB's ``Mandatory Information Requirements for Federal Assistance 
Program Announcements'' (45 FR 39592, June 11, 1980) requires a 
statement concerning the official government programs contained in the 
Catalog of Federal Domestic Assistance. Normally NIH in its 
announcements the number and title of affected individual programs for 
the guidance of the public. Because the guidance in this notice covers 
virtually every NIH and Federal research program in which DNA 
recombinant molecules techniques could be used, it has been determined 
not to be cost effective or in the public interest to attempt to list 
these programs. Such a list would likely require several additional 
pages. In addition, NIH could not be certain that every Federal program 
would be included as many Federal agencies, as well as private 
organizations, both and national and international, have elected to 
follow the NIH Guidelines. In lieu of the individual programs listed in 
the Catalog of Federal Domestic Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.187, Undergraduate 
Scholarship Program for Individuals from Disadvantaged Backgrounds; 
93.22, Clinical Research Loan Repayment Program for Individuals from 
Disadvantaged Backgrounds; 93.232, Loan Repayment Program for 
Research Generally, 93.39, Academic Research Enhancement Award; 
93.936, NIH Acquired Immunodeficiency Syndrome Research Loan 
Repayment Program, National Institutes of Health, HHS)


[[Page 5906]]


    Dated: January 27, 2003.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 03-2620 Filed 2-4-03; 8:45 am]
BILLING CODE 4140-0-M